PCSK9

Earlier this week, we discussed two novel drugs that could potentially revolutionize the treatment and prevention of cardiovascular disease. Both drugs are antibodies, and work by an entirely new mechanism by binding to, and inactivating a protein called PCSK9. PCSK9 plays a part in the regulation of circulating cholesterol (homeostasis).
Now, there is a new option for reducing LDL cholesterol. Regeneron/Sanofi and Amgen each received FDA approval for antibody-based drugs that work by an entirely different mechanism.